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ABSTRACT
The increasing use of invasive medical devices and broad-spectrum antimicrobial agents has resulted in rising candidemia rates throughout the world. 
A 70-year-old diabetic and schizophrenic woman was admitted initially for staphylococcal sepsis secondary to an infected sacral sore but developed 
a catheter-related bloodstream infection caused by extended-spectrum β-lactamase-producing Klebsiella sp. which necessitated the administration 
of meropenem. Unfortunately, after a week on the carbapenem, the bacterial sepsis was followed by candidemia. Parenteral fluconazole therapy was 
started pending identification of the yeast(s). Two distinct Candida species were isolated from her blood which were identified biochemically using ID 
32 C as Candida tropicalis and Candida lipolytica. Both yeasts possessed elevated minimal inhibitory concentrations toward fluconazole and although 
amphotericin B was eventually administered, the patient succumbed to her illness.
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INTRODUCTION
Among the fungi of medical importance, Candida spp. have been 
implicated in up to 90% of invasive fungal infections [1]. Knowing the 
precise species of Candida is not merely of academic interest because the 
mortality rate associated with candidemia is also higher when caused 
by non-albicans Candida (NAC) [2]. This observation is attributable 
to the fact that NAC are notoriously less susceptible to fluconazole 
than C. albicans [3]. Fluconazole has been favored over antifungals 
from other classes due to its relatively low-cost, good tolerability, 
and favorable side effect profile. Thus, the usage of antifungal agents 
from other classes (e.g. polyenes) could potentially expose patients 
to more adverse drug effects. To compound matters, the proportion 
of NAC species causing candidemia has been rising steadily in recent 
years and has in fact overtaken C. albicans as the most common cause 
of candidemia in some centers [4]. This case report discusses the risk 
factors for NAC fungemia as well as its management.
CASE REPORT
A 70-year-old woman with schizophrenia and long-standing diabetes 
mellitus was brought to Universiti Kebangsaan Malaysia Medical Centre 
for high-grade fever for 2 days. For the past 1 year, she has been suffering 
from antipsychotic-induced parkinsonism and has been bedbound 
and dependent on family members for activities of daily living since 
then. On examination, her Glasgow Coma Scale score was 10/15 and 
she appeared dehydrated. Her blood pressure was 106/46 mmHg, 
pulse rate 97 beats per minute, and body temperature 38.2°C and 
her oxygen saturation on room air was 97%. There were fixed flexion 
deformities on both upper limbs and a Grade 3 ulcer was seen over the 
sacral region. The sacral sore contained necrotic tissue and exuded a 
foul-smelling yellowish discharge. Lung, abdominal, and cardiovascular 
examinations were unremarkable.
Preliminary laboratory investigations revealed a high random 
blood glucose level (28 mmol/L), mild anemia (hemoglobin level of 
10.7 g/dL), mild leukocytosis (total white cell count of 14 × 109/L), 
as well as raised serum urea and creatinine levels (31 mmol/L and 
163 µmol/L, respectively). She had metabolic acidosis with a blood pH 
of 7.36, PCO2 of 31.3 mmHg, and a bicarbonate level of 18.5 mmol/L. 
Her urine was negative for ketones. Her initial blood culture grew 
methicillin-susceptible Staphylococcus aureus.
She was initially diagnosed with bacterial sepsis secondary to an 
infected sacral sore. Intravenous (IV) cloxacillin 1 g q8h was started 
along with insulin therapy. A right triple lumen femoral catheter was 
inserted due to difficult peripheral venous access for administration of 
antibiotics. However, while being treated for staphylococcal bacteremia, 
the patient developed another spike of temperature. New blood culture 
specimens were taken from both the femoral catheter and a peripheral 
vein. Both central and peripheral blood cultures yielded extended-
spectrum β-lactamase-producing Klebsiella sp., with a differential time 
to positivity of at least 2 hours. The femoral catheter was subsequently 
removed and IV meropenem 1 g q8h was commenced.
After a week on meropenem, the patient’s clinical condition did not 
appear to have improved and a third blood culture was taken. This time, 
budding yeast cells were seen on the Gram stain of the positive blood 
culture. A statim dose of IV fluconazole 600 mg followed by daily doses 
of 300 mg were administered as empirical therapy while awaiting formal 
identification of the yeast. In the mycology laboratory, the yeast was 
subcultured onto CHROMagar Candida plates, and colonies of two distinct 
colors were formed (i.e., blue and grayish-white) as shown in Fig. 1.
The two yeasts were identified using a commercial biochemical 
identification kit, ID 32 C (bioMérieux, France). The yeast which formed 
blue colonies was identified as Candida tropicalis (numerical profile 
5167340115; 95.4% identification) while the yeast which grew as 
whitish colonies was identified as Candida lipolytica (numerical profile 
2300511211; 99.9% identification). Antifungal susceptibility testing 
was performed on both Candida species with the broth microdilution 
method (Sensititre® YeastOne® YO10) (TREK Diagnostic Systems, 
USA). The minimal inhibitory concentration (MIC) values were read at 
24 h and are shown in Table 1. Following the release of the laboratory 
report, fluconazole therapy was discontinued immediately and IV 
amphotericin B at a dose of 0.5 mg/kg/day was started. Unfortunately, 
the patient succumbed to her illness.
© 2018 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2018.v11i11.28612
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DISCUSSION
In general, among the NAC species, C. tropicalis is one of the three 
most frequently isolated species in candidemia, with the other two 
being C. parapsilosis and C. glabrata [4]. In India, C. tropicalis has the 
distinction of being the most common infecting species [5]. On the other 
hand, C. lipolytica is a relatively obscure NAC species considered to be of 
low virulence, but it is emerging as an important cause of nosocomial 
infections [6]. Both NAC species isolated from our patient were 
fluconazole resistant, in keeping with the belief that NAC are generally 
less susceptible to fluconazole. It is interesting to note that two different 
NAC species were isolated from the same specimen. This finding could 
have been missed if we had not been utilizing chromogenic agars 
(CHROMagar Candida) for routine yeast subcultures in our laboratory. 
CHROMagar Candida has two main benefits over the standard 
Sabouraud dextrose agars in being able to detect mixed cultures and 
provide presumptive identification for C. albicans. Colonies which are 
not green on CHROMagar Candida can be presumptively considered to 
be NAC and subjected to further identification [7].
Like bacteremia, fungemia has also been traditionally regarded as 
a monomicrobial disease, and the isolation of more than one fungal 
species from a blood specimen is an uncommon occurrence [8]. 
Published figures on mixed fungemia vary slightly from region to 
region, with Spanish investigators reporting an incidence of 2.8%, 
Canadian investigators 4%, and the United States investigators 
5.2% [8-10]. However, in all three studies, C. albicans was isolated in more 
than half of the mixed fungemia cases. Thus, the incidence of true mixed 
NAC fungemia is expected to be a lot lower. Since it has already been 
established that invasive monomicrobial NAC infections carry a higher 
mortality than that caused by C. albicans alone, it is worthy to know if 
morbidity/mortality rates for mixed candidemia (in which at least one 
of the organisms is a NAC) would also be amplified. Surprisingly, it has 
been reported that mixed candidemia is not associated with a more 
severe outcome compared to monomicrobial candidemia [8]. However, 
whether this finding can be applied to patients with mixed C. tropicalis 
and C. lipolytica fungemia remains to be ascertained because at the time 
of writing, there are no data in the published literature on this specific 
species combination.
Although there are several risk factors known to be associated with 
candidemia, it is worthwhile to explore if any of these risk factors, 
particularly predispose patients to NAC fungemia. Considering that 
NAC are often less susceptible to fluconazole, it is logical to regard 
prior fluconazole usage as the main risk factor although this was clearly 
not the case with our patient who was on a broad-spectrum antibiotic 
(i.e., meropenem) rather than an antifungal before the candidemia. 
Broad-spectrum antibiotic usage is a non-specific risk factor for 
candidemia, including that caused by C. albicans [9]. On the contrary, 
specific risk factors for NAC fungemia are neutropenia, acute leukemia, 
and other hematological malignancies, prior surgery, catheter 
insertion, and renal failure [4]. Our patient had an indwelling femoral 
catheter and renal impairment (as evidenced by her high serum urea 
and creatinine levels) before the onset of the NAC fungemia. However, 
due to the paucity of clinical data in the medical literature, it remains 
to be corroborated if the insertion of a vascular catheter in a patient 
with underlying renal impairment will predispose him/her to mixed 
C. tropicalis and C. lipolytica fungemia.
Once a diagnosis of NAC fungemia is established, the next course of 
action is prompt and optimal treatment. The two key approaches 
recommended by the Infectious Diseases Society of America in their 
2016 guideline on the management of candidiasis are administering an 
antifungal agent and removing the central venous catheter as early as 
possible. An echinocandin is recommended as the initial therapy, with 
fluconazole and amphotericin B being acceptable alternatives [11]. 
However, the guideline further states that if fluconazole is to be 
administered, the infecting Candida species should be one which is 
unlikely to be fluconazole resistant. Thus, the role of in vitro antifungal 
susceptibility testing is crucial, particularly so when faced with NAC 
species with unpredictable fluconazole susceptibility, as documented 
here. Perhaps, new sources or classes of antifungal agents need to be 
sought and evaluated for human use as well [12,13]. With regard to 
catheter removal, its role in the management of candidemia is especially 
imperative if it is the source of infection. In fact, for some patients 
with C. lipolytica fungemia, catheter removal alone (i.e., without the 
administration of any antifungal agent) has been sufficient in clearing 
the fungemia [6].
CONCLUSION
Both clinicians and laboratorians need to be aware of mixed NAC 
fungemia, particularly in patients who have indwelling central venous 
catheters and other risk factors for candidemia such as renal impairment 
and broad-spectrum antibiotic usage. Clinical mycology laboratories 
are advised to routinely use chromogenic agars when processing yeast-
positive blood cultures and perform antifungal susceptibility testing on 
all NAC species, especially in centers that still favor fluconazole as the 
first-line therapy for candidemia.
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Table 1: MIC values for C. tropicalis and C. lipolytica
Antifungal 
agent
C. tropicalis MIC 
(µg/mL)










Amphotericin B 1 0.5
MIC: Minimal inhibitory concentration, C. tropicalis: Candida tropicalis, 
C. lipolytica: Candida lipolytica
Fig. 1: Distinct bluish and grayish-white yeast colonies on a 
CHROMagar Candida plate
10
Asian J Pharm Clin Res, Vol 11, Issue 11, 2018, 8-10
 Ding and Zaki 
CONFLICTS OF INTEREST
The authors declare that they have no conflicts of interest.
REFERENCES
1. Delaloye J, Calandra T. Invasive candidiasis as a cause of sepsis in the 
critically ill patient. Virulence 2014;5:161-9.
2. Wisplinghoff H, Seifert H, Wenzel RP, Edmond MB. Inflammatory 
response and clinical course of adult patients with nosocomial 
bloodstream infections caused by Candida spp. Clin Microbiol Infect 
2006;12:170-7.
3. Kaur R, Dhakad MS, Goyal R, Kumar R. Emergence of non-albicans 
Candida species and antifungal resistance in intensive care unit patients. 
Asian Pac J Trop Biomed 2016;6:455-60.
4. Krcmery V, Barnes AJ. Non-albicans Candida spp. Causing fungaemia: 
Pathogenicity and antifungal resistance. J Hosp Infect 2002;50:243-60.
5. Kothavade RJ, Kura MM, Valand AG, Panthaki MH. Candida 
tropicalis: Its prevalence, pathogenicity and increasing resistance to 
fluconazole. J Med Microbiol 2010;59:873-80.
6. Zhao Y, Chan JF, Tsang CC, Wang H, Guo D, Pan Y, et al. Clinical 
characteristics, laboratory identification, and in vitro antifungal 
susceptibility of Yarrowia (Candida) lipolytica isolates causing 
fungemia: A multicenter, prospective surveillance study. J Clin 
Microbiol 2015;53:3639-45.
7. Ding CH, Wahab AA, Muttaqillah NA, Tzar MN. Prevalence of 
albicans and non-albicans candiduria in a Malaysian medical centre. 
J Pak Med Assoc 2014;64:1375-9.
8. Jensen J, Muñoz P, Guinea J, Rodríguez-Créixems M, Peláez T, 
Bouza E, et al. Mixed fungemia: Incidence, risk factors, and mortality 
in a general hospital. Clin Infect Dis 2007;44:e109-14.
9. Al-Rawahi GN, Roscoe DL. Ten-year review of candidemia in a 
canadian tertiary care centre: Predominance of non-albicans Candida 
species. Can J Infect Dis Med Microbiol 2013;24:e65-8.
10. Pulimood S, Ganesan L, Alangaden G, Chandrasekar P. Polymicrobial 
candidemia. Diagn Microbiol Infect Dis 2002;44:353-7.
11. Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-
Zeichner L, et al. Clinical practice guideline for the management of 
candidiasis: 2016 update by the Infectious Diseases Society of America. 
Clin Infect Dis 2016;62:e1-50.
12. Dharajiya D, Jasani H, Khatrani T, Kapuria M, Pachchigar K, Patel P. 
Evaluation of antibacterial and antifungal activity of fenugreek (Trigonella 
foenum-graecum) extracts. Int J Pharm Pharm Sci 2016;8:212-7.
13. Pandey S. Antibacterial and antifungal activities of Ocimum 
gratissimum L. Int J Pharm Pharm Sci 2017;9:26-31.
